Mölnlycke and Zuellig Pharma have partnered to offer advanced wound care solutions to the South East Asia market.

The agreement will leverage the experience of Mölnlycke in the marketing, medical and sales management of its advanced wound care portfolio and Zuellig Pharma’s extensive network.

The decision comes after Mölnlycke acquired German wound care products company SastoMed in July last year.

Following the acquisition, Mölnlycke augmented its range of wound care solutions with SastoMed’s oxygen therapy based technology for chronic wounds through its Granulox and Granudacyn products.

Mölnlycke CEO Richard Twomey said: “We are pleased to continue working with our long-standing partner Zuellig Pharma.

“Adding oxygen therapy to our leading range of healing solutions for chronic wounds is a fundamental milestone for Mölnlycke in advancing wound care in this progressive and rapidly developing region.”

SastoMed’s exclusive strategic partner Zuellig Pharma previously managed the commercialisation of Granulox and Granudacyn in South East Asia. This latest partnership will launch the product in specifically targeted locations in South East Asia, with plans to expand to more markets over time.

Zuellig Pharma Commercial Solutions senior vice-president John Graham said: “This new strategic partnership with Mölnlycke is a testament to the confidence our partners have in the work we do and will tap on the deep networks and capabilities we have established across the region to make healthcare more accessible in the communities we serve.”

Zuellig Pharma is a $13bn business with 13,000 employees that covers 13 markets. The company supports more than 350,000 medical facilities worldwide.